Lilly adds "slimming drugs": announced an investment of US$5.3 billion to expand production capacity

Source: Zhao Ying from Wall Street

This is the largest investment in the company's nearly 150-year history.

According to media reports on Friday80freespinsnodepositLilly made a major decision80freespinsnodeposit, announced that it will invest US$5.3 billion to increase the production capacity of tirzepatide, a key ingredient in its weight loss and diabetes injections.

This investment not only adds to existing plans, but is also the largest investment in the company's nearly 150-year history.

This will expand its manufacturing facility in Indiana, which makes tirzepatide, the active ingredient of Zepbound diet drug and diabetes blockbuster Mounjaro.